Authors
Jennifer Neiss, Lisa Hemetsberger, Carolin Schaefer, Marc Rijksen, Antonia Schwab, Armin Zebisch, Andreas Reinisch, Heinz Sill, Annkristin Heine, Albert Wölfler
Published in
Cancer medicine. Volume 15. Issue 11.
Abstract
Acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) are heterogeneous myeloid malignancies with limited therapeutic options and often poor long-term prognosis due to persistence of therapy-resistant leukemic stem cells (LSC). Immunotherapeutic approaches have demonstrated high efficacy in lymphoid malignancies, but their application in AML and CMML remains challenging due to the lack of targetable (neo-)antigens. Here we investigated the expression of the adhesion G protein-coupled receptor E2 (ADGRE2) in diagnostic samples from 124 AML and 28 CMML patients using multiparameter flow cytometry and publicly available expression databases. ADGRE2 was significantly overexpressed on leukemic blasts in both AML and CMML compared to normal CD34+ hematopoietic stem and progenitor cells (HSPCs). ADGRE2 surface expression was high within the CD34+/38- and GPR56high LSC-enriched compartments, comparably distributed with minor differences among subgroups and high in distinct samples with low expression of established immunotherapeutic targets, such as CD33 and CLL-1. Our findings further corroborate ADGRE2 as a promising (complementary) immunotherapeutic target in myeloid malignancies.
PMID:
43001543
Bibliographic data and abstract were imported from PubMed on 09 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0